Stock Track | Praxis Precision Medicines Soars 7.23% Pre-market on Positive Vormatrigine Study Results

Stock Track

Aug 04, 2025

Praxis Precision Medicines, Inc. (PRAX) stock is surging 7.23% in pre-market trading on Monday, following the announcement of positive topline results from its Radiant study of vormatrigine in patients with focal onset seizures.

The company described the results as "Best-in-Disease," signaling a significant breakthrough in the treatment of focal onset seizures. This positive outcome could potentially position Praxis Precision Medicines as a leader in the field of epilepsy treatment, particularly for patients with this specific type of seizure disorder.

Vormatrigine, Praxis Precision Medicines' lead candidate for epilepsy, has shown promising results in this latest study. The success of this clinical trial could have far-reaching implications for the company's future, potentially accelerating the drug's path to market and enhancing the company's value proposition to investors. As the market digests this news, investors will be closely watching for more detailed results and the company's plans for the next steps in vormatrigine's development.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1137998070"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1137998070\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1137998070?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-04 20:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1137998070","market":"nz","top_or_hot":-1,"title":"Stock Track | Praxis Precision Medicines Soars 7.23% Pre-market on Positive Vormatrigine Study Results","media":"Stock Track","content":"<p>Praxis Precision Medicines, Inc. (PRAX) stock is surging 7.23% in pre-market trading on Monday, following the announcement of positive topline results from its Radiant study of vormatrigine in patients with focal onset seizures.</p>\n\n<p>The company described the results as \"Best-in-Disease,\" signaling a significant breakthrough in the treatment of focal onset seizures. This positive outcome could potentially position Praxis Precision Medicines as a leader in the field of epilepsy treatment, particularly for patients with this specific type of seizure disorder.</p>\n\n<p>Vormatrigine, Praxis Precision Medicines' lead candidate for epilepsy, has shown promising results in this latest study. The success of this clinical trial could have far-reaching implications for the company's future, potentially accelerating the drug's path to market and enhancing the company's value proposition to investors. As the market digests this news, investors will be closely watching for more detailed results and the company's plans for the next steps in vormatrigine's development.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Praxis Precision Medicines Soars 7.23% Pre-market on Positive Vormatrigine Study Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Praxis Precision Medicines Soars 7.23% Pre-market on Positive Vormatrigine Study Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-08-04 20:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Praxis Precision Medicines, Inc. (PRAX) stock is surging 7.23% in pre-market trading on Monday, following the announcement of positive topline results from its Radiant study of vormatrigine in patients with focal onset seizures.</p>\n\n<p>The company described the results as \"Best-in-Disease,\" signaling a significant breakthrough in the treatment of focal onset seizures. This positive outcome could potentially position Praxis Precision Medicines as a leader in the field of epilepsy treatment, particularly for patients with this specific type of seizure disorder.</p>\n\n<p>Vormatrigine, Praxis Precision Medicines' lead candidate for epilepsy, has shown promising results in this latest study. The success of this clinical trial could have far-reaching implications for the company's future, potentially accelerating the drug's path to market and enhancing the company's value proposition to investors. As the market digests this news, investors will be closely watching for more detailed results and the company's plans for the next steps in vormatrigine's development.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PRAX","symbol_name":"Praxis Precision Medicines, Inc.","start_time":0,"source_url":"","article_id":"1137998070","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1137998070","pubTimestamp":1754308961,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Praxis Precision Medicines, Inc. (PRAX) stock is surging 7.23% in pre-market trading on Monday, following the announcement of positive topline results from its Radiant study of vormatrigine in...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PRAX":"Praxis Precision Medicines, Inc."},"translate_title":"个股追踪|Praxis Precision Medicines盘前大涨7.23%Vormatrigine研究结果利好","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRAX":1},"content_text":"Praxis Precision Medicines, Inc. (PRAX) stock is surging 7.23% in pre-market trading on Monday, following the announcement of positive topline results from its Radiant study of vormatrigine in patients with focal onset seizures.\nThe company described the results as \"Best-in-Disease,\" signaling a significant breakthrough in the treatment of focal onset seizures. This positive outcome could potentially position Praxis Precision Medicines as a leader in the field of epilepsy treatment, particularly for patients with this specific type of seizure disorder.\nVormatrigine, Praxis Precision Medicines' lead candidate for epilepsy, has shown promising results in this latest study. The success of this clinical trial could have far-reaching implications for the company's future, potentially accelerating the drug's path to market and enhancing the company's value proposition to investors. As the market digests this news, investors will be closely watching for more detailed results and the company's plans for the next steps in vormatrigine's development.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}